Literature DB >> 15742395

High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells.

Bin Lou1, Xue-Ling Liao, Man-Ping Wu, Pei-Fang Cheng, Chun-Yan Yin, Zheng Fei.   

Abstract

AIM: To investigate the possibility of recombinant high-density lipoprotein (rHDL) being a carrier for delivering antitumoral drug to hepatoma cells.
METHODS: Recombinant complex of HDL and aclacinomycin (rHDL-ACM) was prepared by cosonication of apoproteins from HDL (Apo HDL) and ACM as well as phosphatidylcholine. Characteristics of the rHDL-ACM were elucidated by electrophoretic mobility, including the size of particles, morphology and entrapment efficiency. Binding activity of rHDL-ACM to human hepatoma cells was determined by competition assay in the presence of excess native HDL. The cytotoxicity of rHDL-ACM was assessed by MTT method.
RESULTS: The density range of rHDL-ACM was 1.063-1.210 g/mL, and the same as that of native HDL. The purity of all rHDL-ACM preparations was more than 92%. Encapsulated efficiencies of rHDL-ACM were more than 90%. rHDL-ACM particles were typical sphere model of lipoproteins and heterogeneous in particle size. The average diameter was 31.26+/-5.62 nm by measure of 110 rHDL-ACM particles in the range of diameter of lipoproteins. rHDL-ACM could bind on SMMC-7721 cells, and such binding could be competed against in the presence of excess native HDL. rHDL-ACM had same binding capacity as native HDL. The cellular uptake of rHDL-ACM by SMMC-7721 hepatoma cells was significantly higher than that of free ACM at the concentration range of 0.5-10 microg/mL (P<0.01). Cytotoxicity of rHDL-ACM to SMMC-7721 cells was significantly higher than that of free ACM at concentration range of less than 5 microg/mL (P<0.01) and IC50 of rHDL-ACM was lower than IC50 of free ACM (1.68 nmol/L vs 3 nmol/L). Compared to L02 hepatocytes, a normal liver cell line, the cellular uptake of rHDL-ACM by SMMC-7721 cells was significantly higher (P<0.01) and in a dose-dependent manner at the concentration range of 0.5-10 microg/mL. Cytotoxicity of the rHDL-ACM to SMMC-7721 cells was significantly higher than that to L02 cells at concentration range of 1-7.5 microg/mL (P<0.01). IC50 for SMMC-7721 cells (1.68 nmol/L) was lower than that for L02 cells (5.68 nmol/L), showing a preferential cytotoxicity of rHDL-ACM for SMMC-7721 cells.
CONCLUSION: rHDL-ACM complex keeps the basic physical and biological binding properties of native HDL and shows a preferential cytotoxicity for SMMC-7721 hepatoma to normal L02 hepatocytes. HDL is a potential carrier for delivering lipophilic antitumoral drug to hepatoma cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15742395      PMCID: PMC4250784          DOI: 10.3748/wjg.v11.i7.954

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells.

Authors:  P J Pussinen; H Lindner; O Glatter; H Reicher; G M Kostner; A Wintersperger; E Malle; W Sattler
Journal:  Biochim Biophys Acta       Date:  2000-05-31

2.  Scavenger receptor BI (SR-BI) mediates a higher selective cholesteryl ester uptake from LpA-I compared with LpA-I:A-II lipoprotein particles.

Authors:  Franz Rinninger; May Brundert; Ralph-M Budzinski; Jean-Charles Fruchart; Heiner Greten; Graciela R Castro
Journal:  Atherosclerosis       Date:  2003-01       Impact factor: 5.162

3.  Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins.

Authors:  M Masquelier; G Tirzitis; C O Peterson; M Pålsson; A Amolins; M Plotniece; A Plotniece; N Makarova; S G Vitols
Journal:  Eur J Med Chem       Date:  2000-04       Impact factor: 6.514

4.  Sequential flotation ultracentrifugation.

Authors:  V N Schumaker; D L Puppione
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

Review 5.  Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.

Authors:  P C Rensen; R L de Vrueh; J Kuiper; M K Bijsterbosch; E A Biessen; T J van Berkel
Journal:  Adv Drug Deliv Rev       Date:  2001-04-25       Impact factor: 15.470

Review 6.  In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport.

Authors:  M N Pieters; D Schouten; T J Van Berkel
Journal:  Biochim Biophys Acta       Date:  1994-01-11

7.  Forms of human serum high density lipoprotein protein.

Authors:  A Scanu
Journal:  J Lipid Res       Date:  1966-03       Impact factor: 5.922

8.  Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles.

Authors:  M K Bijsterbosch; D Schouten; T J van Berkel
Journal:  Biochemistry       Date:  1994-11-29       Impact factor: 3.162

9.  Preparation of biologically active analogs of serum low density lipoprotein.

Authors:  B Lundberg; L Suominen
Journal:  J Lipid Res       Date:  1984-06       Impact factor: 5.922

10.  Plasma lipoproteins as targeting carriers to tumour tissues after administration of a lipophilic agent to mice.

Authors:  T Tokui; C Kuroiwa; S Muramatsu; Y Tokui; K Sasagawa; T Ikeda; T Komai
Journal:  Biopharm Drug Dispos       Date:  1995-03       Impact factor: 1.627

View more
  20 in total

Review 1.  Metabolism of high density lipoproteins in liver cancer.

Authors:  Jing-Ting Jiang; Ning Xu; Chang-Ping Wu
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

2.  Detecting the functional complexities between high-density lipoprotein mimetics.

Authors:  Yoshitaka J Sei; Jungho Ahn; Taeyoung Kim; Eunjung Shin; Angel J Santiago-Lopez; Seung Soon Jang; Noo Li Jeon; Young C Jang; YongTae Kim
Journal:  Biomaterials       Date:  2018-04-06       Impact factor: 12.479

Review 3.  SR-B1: A Unique Multifunctional Receptor for Cholesterol Influx and Efflux.

Authors:  Wen-Jun Shen; Salman Azhar; Fredric B Kraemer
Journal:  Annu Rev Physiol       Date:  2017-11-10       Impact factor: 19.318

4.  Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells.

Authors:  Xiao Gu; Wenli Zhang; Jianping Liu; John P Shaw; Yuanjun Shen; Yiming Xu; Hui Lu; Zimei Wu
Journal:  AAPS PharmSciTech       Date:  2011-09-17       Impact factor: 3.246

Review 5.  Circulating miRNAs: reflecting or affecting cardiovascular disease?

Authors:  Vanessa P M van Empel; Leon J De Windt; Paula A da Costa Martins
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

6.  Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting.

Authors:  Jie Tang; Rui Kuai; Wenmin Yuan; Lindsey Drake; James J Moon; Anna Schwendeman
Journal:  Nanomedicine       Date:  2017-04-18       Impact factor: 5.307

7.  Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers.

Authors:  Ian R Corbin; Kenneth K Ng; Lili Ding; Andrea Jurisicova; Gang Zheng
Journal:  Nanomedicine (Lond)       Date:  2012-10-15       Impact factor: 5.307

8.  Role of lipids in spheroidal high density lipoproteins.

Authors:  Timo Vuorela; Andrea Catte; Perttu S Niemelä; Anette Hall; Marja T Hyvönen; Siewert-Jan Marrink; Mikko Karttunen; Ilpo Vattulainen
Journal:  PLoS Comput Biol       Date:  2010-10-28       Impact factor: 4.475

9.  High-Density Lipoproteins for Therapeutic Delivery Systems.

Authors:  R Kannan Mutharasan; Linda Foit; C Shad Thaxton
Journal:  J Mater Chem B       Date:  2015-11-24       Impact factor: 6.331

Review 10.  Lipids changes in liver cancer.

Authors:  Jing-Ting Jiang; Ning Xu; Xiao-Ying Zhang; Chang-Ping Wu
Journal:  J Zhejiang Univ Sci B       Date:  2007-06       Impact factor: 3.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.